- Biotech company MindBio Therapeutics (CSE:MBIO) filed a patent application for the world’s first AI model capable of detecting alcohol and drug use though vocal analysis.
- The technology offers clear appeal across heavily regulated industries, holding the potential for multiple revenue streams once commercial testing gets underway in Q2.
- MindBio stock last traded at C$0.98 and has given back 75.50 per cent year-over-year.
Biotech company MindBio Therapeutics (CSE:MBIO) filed a patent application for the world’s first AI model capable of detecting alcohol and drug use though vocal analysis.
The technology, vastly more efficient than typical breath and urine-based methods, uses more than 50 million data points to detect intoxication, promising widespread utility across industries where substance abuse testing in mandated by regulators, including mining, construction, law enforcement and aviation.
“The digital health diagnostics market represents a significant opportunity for MindBio to leverage its voice AI diagnostics technology with a first-mover commercialization advantage in drug and alcohol intoxication detection,” Justin Hanka, chief executive officer of MindBio Therapeutics, said in Wednesday’s news release.
When MindBio releases its Edge AI intoxication detection kiosks for commercial testing in Q2 2026, the company believes it will set a new standard for drug and alcohol testing with an immediate value add.
About MindBio Therapeutics
MindBio is a biotech company commercializing AI technologies for the detection of drug and alcohol intoxication via voice analysis.
MindBio stock (CSE:MBIO) last traded at C$0.98 and has given back 75.50 per cent year-over-year.
Join the discussion: Find out what investors are saying about this AI-powered biotech stock on the MindBio Therapeutics Corp. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
